原发性雷珠单抗治疗后早产儿视网膜病变的短期再激活
该回顾性研究分析了2013至2023年间接受玻璃体腔注射雷珠单抗0.25 mg/0.025 cc治疗1型早产儿视网膜病变的43例患者82只眼,发现30.2%的患者(26.8%的眼)在治疗后平均7.2周出现短期再激活;再激活风险与I区病变、首次注射时较低矫正胎龄和较低出生胎龄相关;重复注射有效且眼部不良事件少,但再次再激活风险仍存在。
要点
- 43例患者82只眼中,13例(22只眼)出现短期再激活,占患者30.2%、眼26.8%,平均发生于治疗后7.2周。
- 再激活风险与I区病变(OR 6.23)、首次注射时较低矫正胎龄(OR 1.64)、较低出生胎龄(OR 1.80)相关。
- 13例接受重复注射的患者中5例因第二次再激活需激光治疗,占接受玻璃体腔注射雷珠单抗患者的11.6%。
核心结论
- 原发性玻璃体腔注射雷珠单抗治疗侵袭性早产儿视网膜病变后可能需要重复注射;重复注射治疗有效且眼部不良事件少,但再次再激活仍是风险。
研究设计与样本
- 回顾性病历审查研究,纳入2013年至2023年在UCLA医疗系统内住院筛查早产儿视网膜病变并接受玻璃体腔注射雷珠单抗的患者。
主要发现
- 43例患者82只眼接受原发性玻璃体腔注射雷珠单抗0.25 mg/0.025 cc治疗1型早产儿视网膜病变。
- 13例患者(22只眼)出现短期再激活,占患者30.2%、眼26.8%,平均发生于治疗后7.2周±1.7周。
- 再激活风险与I区病变相关(比值比6.23,95%CI 1.35-28.7,P=0.019)。
- 再激活风险与首次注射时较低矫正胎龄相关(比值比1.64,95%CI 1.19-2.26,P=0.003)。
- 再激活风险与较低出生胎龄相关(比值比1.80,95%CI 1.04-3.13,P=0.037)。
关键数值与推荐
- 短期再激活定义为矫正胎龄52周前早产儿视网膜病变再次加重至2期或3期。
- 13例接受重复注射的患者中,5例因第二次再激活需激光治疗,占接受玻璃体腔注射雷珠单抗患者的11.6%。
- 无眼发生视网膜血管阻塞、眼内炎或白内障。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Investigate risk factors for short-term reactivation of retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) therapy and determine safety and efficacy of repeat injections. METHODS: Retrospective chart review study of patients screened for ROP as inpatients between 2013 and 2023 who received IVR within the UCLA health care system. Primary outcomes were rates and timing of short-term ROP reactivation, defined as repeat worsening of ROP to stage 2 or 3 before 52 weeks postmenstrual age, as well as risk factors for reactivation. Other outcomes included adverse events and rates of reactivation after a second intravitreal injection. RESULTS: Eighty-two eyes of 43 patients received primary IVR 0.25 mg/0.025 cc for type 1 ROP. Thirteen patients (22 eyes) (30.2% of patients, 26.8% of eyes) developed short-term reactivation an average of 7.2 weeks ± 1.7 weeks after treatment. Increased reactivation risk was associated with zone I disease (odds ratio 6.23, 95% CI, 1.35-28.7, P = 0.019), lower postmenstrual age at first injection (odds ratio 1.64, 95% CI, 1.19-2.26; P = 0.003), and lower gestational age at birth (odds ratio 1.80, 95% CI, 1.04-3.13, P = 0.037). Of the 13 patients that received repeat injections, five required laser treatment for a second reactivation (11.6% of patients receiving IVR). No eyes developed retinal vascular occlusion, endophthalmitis, or cataract. CONCLUSION: Repeat injections may be required after primary IVR for aggressive ROP. Repeat IVR treatment for ROP is effective and poses few ophthalmic adverse events, although additional reactivation remains a risk.
引用
- Strawbridge J, Cheng JY, Gundlach BS, et al. SHORT-TERM REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER PRIMARY RANIBIZUMAB TREATMENT. Retina. 2024. PMID: 39024625. doi:10.1097/IAE.0000000000004206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。